EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

The Treatment Strategies for Intermediate‐Advanced Hepatocellular Carcinoma Based on Albumin–Bilirubin Grade: A Multicenter Retrospective Cohort Study

Kang Liang iD, Jianwei Liu, Xiaorong Pan iD, Yuxuan Lin iD, Kongying Lin iD, Hui Xue, Jing Li iD, Huichuan Sun iD, Kui Wang iD, China Liver Cancer Study Group Young Investigators (CLEAP)

Cancer Medicine · 2026-11 · 15 (11)

DOI: 10.1002/cam4.72415 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, online erschienen am 05.11.2026. Verfasst von Kang Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bilirubin, Serum Albumin. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Three-Year Action Plan for Clinical Skills and Innovation Capacity Enhancement of Tertiary Hospitals in Shanghai, Meng Chao Talent Leadership Reserve Training Program, Shanghai Science and Technology Commission Explorer Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate whether the albumin–bilirubin (ALBI) grade modifies the association of combined locoregional plus systemic therapy versus systemic therapy alone with outcomes in unresectable hepatocellular carcinoma (HCC).

Methods

This multicente retrospective study enrolled 525 patients, stratified by the established ALBI grade cut‐off into ALBI‐low (Grade 1, ALBI score ≤ −2.60, n = 257) and ALBI‐high (Grade 2/3, n = 268). Propensity score matching (PSM) was performed in the whole cohort and within each ALBI stratum; survival, tumor response, and safety were compared in matched cohorts, with effect modification tested by a treatment × ALBI interaction term.

Results

After PSM, combination therapy was associated with better overall survival (OS) (hazard ratio [HR] 0.51, 95% confidence interval [CI] 0.34–0.76; p = 0.001) and progression‐free survival (PFS) (HR 0.73, 95% CI 0.56–0.96; p = 0.024). The association was observed in ALBI‐low patients (OS: HR 0.32, 95% CI 0.18–0.56, p < 0.001; PFS: HR 0.59, 95% CI 0.41–0.85, p = 0.004), who also had higher objective response rates by modified Response Evaluation Criteria in Solid Tumors (mRECIST; 70.9% vs. 38.8%, p < 0.001) and RECIST 1.1 (55.3% vs. 30.1%, p < 0.001). No significant association was seen in ALBI‐high patients (OS: HR 0.83, 95% CI 0.47–1.45, p = 0.504; PFS: HR 1.06, 95% CI 0.71–1.58, p = 0.792), and the treatment × ALBI interaction was significant for OS ( p = 0.019) and PFS ( p = 0.035). Overall and Grade 3–4 adverse reactions were comparable, but elevated bilirubin (33.0% vs. 17.0%, p = 0.012) and transaminases (35.1% vs. 20.2%, p = 0.022) were more frequent with combination therapy in the ALBI‐high cohort.

Conclusion

In this multicenter real‐world cohort, combination therapy was associated with better outcomes in patients of ALBI Grade 1 but not Grade 2/3, in whom hepatic toxicity was more frequent, and the exploratory treatment × ALBI interaction was significant. ALBI grade may help identify patients more likely to benefit from combined locoregional and systemic therapy, although prospective validation is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsBilirubinSerum AlbuminHumansRetrospective StudiesFemaleMaleMiddle AgedAged

Stichwörter der Autor:innen

HAICTACEalbumin–bilirubinhepatocellular carcinomaprognosis

Substanzen

BilirubinSerum Albumin

Autor:innen und Institutionen

  • School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
  • Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Shanghai, China.
  • Shanghai Baoshan District Songnan Town Community Health Center, Shanghai, China.
  • Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Kang Liang, Xiaorong Pan, Yuxuan Lin, Kongying Lin, Jing Li, Huichuan Sun, Kui Wang

Förderung

  • Three-Year Action Plan for Clinical Skills and Innovation Capacity Enhancement of Tertiary Hospitals in Shanghai
  • Meng Chao Talent Leadership Reserve Training Program
  • Shanghai Science and Technology Commission Explorer Program
  • Shanghai Municipal Health Commission Research Project
  • Jiading District Health Commission 2025 Research Project
  • Third Affiliated Hospital of the Naval Medical University 2025 Department Project-Clinical Research Training Program
  • Tengfei Engineering Talent Cultivation Program of Third Affiliated Hospital of Naval Medical University

Zitieren

APA

Liang, K., Liu, J., Pan, X., Lin, Y., Lin, K., Xue, H., Li, J., Sun, H., Wang, K., & China Liver Cancer Study Group Young Investigators (CLEAP) (2026). The Treatment Strategies for Intermediate‐Advanced Hepatocellular Carcinoma Based on Albumin–Bilirubin Grade: A Multicenter Retrospective Cohort Study. Cancer Medicine, 15(11). https://doi.org/10.1002/cam4.72415

Vancouver

Liang K, Liu J, Pan X, Lin Y, Lin K, Xue H, et al. The Treatment Strategies for Intermediate‐Advanced Hepatocellular Carcinoma Based on Albumin–Bilirubin Grade: A Multicenter Retrospective Cohort Study. Cancer Medicine. 2026;15(11). doi:10.1002/cam4.72415

BibTeX
@article{Liang2026,
  author = {Liang, Kang and Liu, Jianwei and Pan, Xiaorong and Lin, Yuxuan and Lin, Kongying and Xue, Hui and Li, Jing and Sun, Huichuan and Wang, Kui and China Liver Cancer Study Group Young Investigators (CLEAP), China Liver Cancer Study Group Young Investigators (CLEAP)},
  title = {The Treatment Strategies for Intermediate‐Advanced Hepatocellular Carcinoma Based on Albumin–Bilirubin Grade: A Multicenter Retrospective Cohort Study},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {11},
  doi = {10.1002/cam4.72415}
}
Kostenlos starten →